17 December 2020 in Blood Advances
MKMayte Sánchez van Kammen
+30
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 months. The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and principal safety outcome, major or clinically relevant nonmajor bleeding,were centrally evaluated by blinded investigators. Sinus recanalization on repeat brain imaging was a secondary outcome. Statistical analyses were exploratory. In total, 114 children with confirmed CVT were randomized. All children completed the follow-up. None of the 73 rivaroxaban recipients and 1 (2.4%; CVT) of the 41 standard anticoagulant recipients had symptomatic, recurrent VTE after 3 months (absolute difference, 2.4%; 95% confidence interval [CI], −2.6% to 13.5%). Clinically relevant bleeding occurred in 5 (6.8%; all nonmajor and noncerebral) rivaroxaban recipients and in 1 (2.5%; major [subdural] bleeding) standard anticoagulant recipient (absolute difference, 4.4%; 95% CI, −6.7% to 13.4%). Complete or partial sinus recanalization occurred in 18 (25%) and 39 (53%) rivaroxaban recipients and in 6 (15%) and 24 (59%) standard anticoagulant recipients, respectively. In summary, in this substudy of a randomized trial with a limited sample size, children with CVT treated with rivaroxaban or standard anticoagulation had a low risk of recurrent VTE and clinically relevant bleeding. This trial was registered at clinicaltrials.gov as #NCT02234843.
27 September 2022 in Blood Advances
In the phase 2b/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. In a single-arm, phase 3, secondary VTE prevention study, up to 12 months dabigatran use was associated with favorable safety. Dabigatran is approved by the European Medicines Agency and US Food and Drug Administration for pediatric indications. We assessed primary composite efficacy (complete thrombus resolution and freedom from VTE recurrence/VTE-related death) in subgroups with thrombophilia vs those with negative/unknown thrombophilia status in the DIVERSITY trial and safety in both studies. Thrombophilia types were similar between the DIVERSITY trial (total population) and secondary prevention studies: factor V Leiden, 42% vs 33%; prothrombin mutation (G20210A), 19% vs 17%; antithrombin deficiency, 15% vs 20%; protein C/S deficiency, 23% vs 25%; and antiphospholipid antibodies, 18% vs 20% of patients, respectively. In DIVERSITY, 36% and 22% of thrombophilia subgroup patients treated with dabigatran and SOC, respectively, met the primary end point (Mantel-Haenszel–weighted rate difference, −0.135; 95% confidence interval, −0.36 to 0.08; noninferiority P = .0014); comparable to the total DIVERSITY trial population (46% vs 42%) showing dabigatran noninferiority to SOC. Within this subgroup, numerically fewer patients experienced VTE recurrence or progression of index thrombus in the dabigatran treatment group vs SOC. In the secondary prevention study, VTE recurrence at 12 months occurred in 2.8% of patients with thrombophilia vs 0% with negative/unknown thrombophilia. Safety profiles were consistent with those reported previously. Although they should be interpreted with caution, these exploratory findings suggest dabigatran could be an appropriate long-term anticoagulant for children with thrombophilia. These trials were registered at www.clinicaltrials.gov as #NCT01895777 and #NCT02197416.
23 May 2024 in Perm Medical Journal
Objective. To develop criteria for prognosis of the outcome of ischemic stroke, taking into account age, dynamics of state assessment, the Rankin and NIHSS scales readings and the fact of disability in the long-term period. The universal reliable criteria, that allow to predict the outcome of ischemic stroke, have not been developed yet. Material and methods. The study group consisted of 246 patients with ischemic stroke aged 18 to 44 who were observed from 2008 to 2021. Results. It is impossible to predict disability in a long-term period of ischemic stroke reliably. Predicting the outcome of ischemic stroke using the Rankin and NIHSS scales is significant in the acute period and allows to predict the dynamics of recovery in mild and moderate cases. Conclusion. The predictive value of the integrative indicators of the patient's condition, assessed by the Rankin and NIHSS scales, has been established.
1 January 2017 in AIP Conference Proceedings
The work deals with the application of neural networks residual kriging (NNRK) to the spatial prediction of the abnormally distributed soil pollutant (Cr). It is known that combination of geostatistical interpolation approaches (kriging) and neural networks leads to significantly better prediction accuracy and productivity. Generalized regression neural networks and multilayer perceptrons are classes of neural networks widely used for the continuous function mapping. Each network has its own pros and cons; however both demonstrated fast training and good mapping possibilities. In the work, we examined and compared two combined techniques: generalized regression neural network residual kriging (GRNNRK) and multilayer perceptron residual kriging (MLPRK). The case study is based on the real data sets on surface contamination by chromium at a particular location of the subarctic Novy Urengoy, Russia, obtained during the previously conducted screening. The proposed models have been built, implemented and validated using ArcGIS and MATLAB environments. The networks structures have been chosen during a computer simulation based on the minimization of the RMSE. MLRPK showed the best predictive accuracy comparing to the geostatistical approach (kriging) and even to GRNNRK.
6 March 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To analyze the effectiveness of Relatox (Botulinum toxin type A — hemagglutinin complex) in comparison with Botox in the treatment of primary idiopathic blepharospasm. Material and methods. The study included clinical data for 21 patients with blepharospasm who were treated by botulinum therapy with Botox and Relatox for 3 years. The research method is a one-step retrospective analysis of medical data. Injections were carried out with a 3-month interval. On the 6th cycle, the drug was switched to Relatox. The clinical efficacy of the drugs was assessed using an 8-point Jankovich evaluation scale: the average values before the injection and 14 days after it were compared for each procedure. Results. Mean Jankovich scale scores decreased 2.5-fold for all cycles by the second week after the procedure (4.95 pre-injection vs. 1.8 post-injection), and the mean paired Student’s T-criterion for all injections was 7.14 (with a critical value of 2.021 and a significance level of p=0.05). The mean paired Student’s T-criterion for Botox was –6.63 and for Relatox –7.5 (with a critical value of 2.021 and a significance level of p=0.05), indicating a high efficacy of both drugs, slightly higher for Relatox. Conclusion. A consistent trend of increasing efficacy with regular botulinum toxin injections and greater efficacy of Relatox compared to Botox in the treatment of patients with primary idiopathic blepharospasm has been demonstrated.
1 January 2016 in S.S. Korsakov Journal of Neurology and Psychiatry